# SaLuDo (NCT06088290)

> Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

No report yet. It can be ordered.

- Drugs tested: lurbinectedin
- Indication: first-line metastatic leiomyosarcoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06088290
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: PharmaMar
- Conditions: Leiomyosarcoma
- Interventions: Lurbinectedin; Doxorubicin
- Enrollment: 469
- Primary outcome: PFS by IRC

## Indexed commentary on SaLuDo so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=saludo-nct06088290
